Kiniksa Pharmaceuticals International (KNSA) reported $678M in revenue for fiscal 2025, +60.1% year on year. That ranks #2026 by revenue among 2853 SEC filers and #192 in Healthcare. Net income was $59.0M, a net margin of 8.7%. Revenue has grown 104.8% a year on average since 2021 ($38.5M then). The fiscal 2025 balance sheet shows $764M in total assets and $166M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $678M | +60.1% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $77.2M | +$123M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $59.0M | +$102M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $138M | +437.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.6M | +466.1% | FY20252025-12-31 |
| Total assetsAssets | $764M | +31.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $568M | +29.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $166M | −9.8% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $214M | $22.6M | Open → |
| Q2 20262026-06-30 | $244M | $25.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Kiniksa Pharmaceuticals International, Plc
- Ticker
- KNSA
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001730430
Filings
- 10-QJul 28, 2026Open filing →
- 10-QApr 28, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Amphastar PharmaceuticalsAMPH | $720M | $98.1M |
| Supernus PharmaceuticalsSUPN | $719M | −$38.6M |
| Avanos MedicalAVNS | $701M | −$72.9M |
| Kiniksa Pharmaceuticals InternationalKNSA | $678M | $59.0M |
| SNDLSNDL | $677M | −$11.3M |
| Ultragenyx PharmaceuticalRARE | $673M | −$575M |
| Cresco LabsCRLBF | $656M | −$135M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Kiniksa Pharmaceuticals International — Key figures |url=https://companiesranked.com/en/company/kiniksa-pharmaceuticals-international |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Kiniksa Pharmaceuticals International — Key figures. CompaniesRanked. https://companiesranked.com/en/company/kiniksa-pharmaceuticals-internationalBibTeX
@misc{companiesranked-en-company-kiniksa-pharmaceuticals-international-2026,
author = {{CompaniesRanked}},
title = {{Kiniksa Pharmaceuticals International — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/kiniksa-pharmaceuticals-international}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-019168 · February 24, 2026
{{cite web |title=Kiniksa Pharmaceuticals International — Key figures — 10-K (0001104659-26-019168) |url=https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/knsa-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.